Result of General Meeting

RNS Number : 0991Z

Oxford Biomedica PLC

07 January 2011

 



OXFORD BIOMEDICA PLC
("Oxford BioMedica" or the "Company")

GENERAL MEETING

Oxford BioMedica (LSE: OXB), a biopharmaceutical company developing gene-based medicines and therapeutic vaccines, announces that all resolutions proposed were duly passed at its General Meeting, held today in London.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk (located on pages 156 to 158 of the prospectus dated 13 December 2010).

In accordance with the Company's obligations under Listing Rule 9.6.2, copies of the resolutions passed at the General Meeting have been submitted to the National Storage Mechanism and will shortly be available for viewing at http://www.hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below. On the Record Date (10 December 2010) there were 544,875,557 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
Ordinary resolutions
1	165,363,035	602,268	379,129	92,215	786,126	166,436,647	Passed
2	165,123,318	862,721	379,129	53,468	804,137	166,418,636	Passed
4	97,441,672	648,135	379,129	160,484	68,593,353	98,629,420	Passed
5	165,096,664	657,295	379,129	199,525	890,160	166,332,613	Passed
Special resolution
3	164,846,001	640,898	379,129	416,975	939,770	166,283,003	Passed

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer	Tel: [phone]
Singer Capital Markets Limited Shaun Dobson/ Claes Spång	Tel: [phone]
Media/Financial Enquiries: Emma Thompson/Rob Newman/Amber Bielecka M:Communications	Tel: [phone]
US Enquiries: Simon Harnest The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector^®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

REGFDLFBFFFLBBV